Who Is Buying Pfizer? Hedge Fund Activity in 2026
See which hedge funds are buying, selling, or holding Pfizer (PFE) based on latest 13F filings. 6 funds buying, institutional value $24.8B.
8 min czytaniaFact-checked against primary sources on · figures re-verified on regulator, issuer or SEC filings — not copied from other sites
Who Is Buying Pfizer? Hedge Fund Activity in 2026
Pfizer, the pharmaceutical giant behind the COVID-19 vaccine blockbuster, has been navigating a turbulent post-pandemic era. At around $28.32 per share, PFE trades well below its pandemic highs as investors grapple with declining COVID revenues, pipeline uncertainty, and the massive Seagen acquisition integration. Yet the stock's depressed valuation and hefty dividend yield are creating a battleground — and hedge funds are firmly split.
With 19 active funds tracked, Pfizer generates one of the most divided institutional ownership profiles in our universe. The 13F data reveals a fascinating tug-of-war between bulls seeing deep value and bears still heading for the exits.
Quick Answer
Across the funds we read directly from SEC filings, the largest Pfizer position in the Q2 2026 13Fs (period ending 30 June 2026) is Citadel Advisors at $149M (6,191,186 shares). Measured against the size of each filer's book rather than in dollars, the most concentrated holder is Citadel Advisors, where Pfizer is 0.1% of everything they report. Every figure here is aggregated by CUSIP from the filer's own information table with put/call rows excluded — a 13F lists options beside shares, and adding them together is what produces the inflated stakes quoted elsewhere. Filings lag roughly 45 days: this is positioning as of 30 June 2026, not today, and not investment advice.
Pfizer Institutional Snapshot
| Metric | Value |
|---|---|
| Funds Buying | 6 |
| Funds Selling | 7 |
| Funds Holding | 6 |
| Active Funds Tracked | 19 |
| Share Price | ~$28.32 |
With 7 sellers outnumbering 6 buyers, Pfizer is one of the few stocks in our coverage where the selling pressure exceeds buying at the institutional level. This bearish tilt deserves careful examination.
Who holds Pfizer, and how much it matters to them
Read from each filer's Q2 2026 information table (period ending 30 June 2026).
| Fund | Position | Shares | Share of the fund's 13F book |
|---|---|---|---|
| Citadel Advisors | $149M | 6,191,186 | 0.1% of $171.84B |
| Millennium Management | $13M | 556,133 | 0.0% of $142.92B |
| Bridgewater Associates | $4.3M | 180,092 | 0.0% of $24.38B |
The last column is the one worth reading. A multi-strategy fund reporting a $100B+ book can hold a large dollar amount of Pfizer that means almost nothing to it, while a concentrated fund holding less in dollars may have several percent of its entire book in the name. Rankings by dollar value hide exactly that difference.
Savings in one bank, investments in another? See it all in one place — and how many months it could carry you.
See your Freedom Runway — freeWho added and who cut
Comparing each filer's Q1 2026 table with its Q2 2026 one, by share count — the change is what shows conviction, not the size of the position.
| Fund | Q1 2026 shares | Q2 2026 shares | Change |
|---|---|---|---|
| Bridgewater Associates | 0 | 180,092 | new position |
| Millennium Management | 96,364 | 556,133 | +477% |
| Citadel Advisors | 7,359,865 | 6,191,186 | -16% |
A fund absent from this table reported no Pfizer position in either quarter.
Related Articles
- Who Is Buying NVIDIA? Hedge Fund Activity in 2026
- Who Is Buying Apple? Hedge Fund Activity in 2026
- Who Is Buying Tesla? Hedge Fund Activity in 2026
FAQ
Why is institutional sentiment on Pfizer so split?
PFE sits at the intersection of a structural revenue cliff (post-COVID vaccine and Paxlovid normalization) and a major M&A bet (the $43B Seagen acquisition). Bulls underwrite the oncology pipeline and dividend; bears focus on the patent cliff and integration risk — which is why 13F flows show 6 buyers, 7 sellers and 6 holders almost evenly balanced.
What is the Seagen acquisition and why does it matter?
Seagen brought Pfizer a leading antibody-drug conjugate (ADC) platform and several commercial oncology assets. The bull thesis is that ADC revenue and pipeline readouts replace declining COVID franchises through the late 2020s; the bear thesis is that the $43B price tag and integration drag weigh on returns before that contribution shows up.
Why does Baker Bros' reduction carry extra weight?
Baker Bros is a healthcare and biotech specialist — drug pipelines, FDA dynamics and competitive landscapes are their core competency. When a sector-specialist fund trims a name like PFE, it tends to carry more informational weight than a generalist sale because it reflects deep diligence on the actual pipeline.
Is Pfizer's dividend sustainable at current levels?
The dividend yield is historically high because the share price has fallen, not because the payout itself was cut. Institutional holders typically model dividend sustainability against free cash flow ex-COVID and the cost of integrating Seagen — the current consensus is that the dividend is covered, but with less cushion than during the COVID windfall years.
How can I follow PFE hedge fund positioning over time?
Freenance Smart Money tracks 13F filings from major funds quarter over quarter, so you can see whether contrarians like Canyon Capital keep adding, whether Baker Bros stabilizes or reduces further, and whether the systematic funds re-enter. That side-by-side view is the most useful way to monitor whether the "split sentiment" is resolving in either direction.